The clinical courses of multiple sclerosis were defined in 1996 and refined in 2013 to
provide a time-based assessment of the current status of the individual. These definitions …

Glial cells play crucial roles in brain homeostasis and pathogenesis of central nervous
system (CNS) injuries and diseases. However, the roles of these cells and the molecular …

MRI plays a central role in the diagnosis of multiple sclerosis (MS) and in the monitoring of
disease course and treatment response. Advanced MRI techniques have shed light on MS …

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system
characterized by myelin loss and neuronal dysfunction. Although the majority of patients do …

Understanding the mode of action of drugs is a challenge with conventional methods in
clinical trials. Here, we aimed to explore whether simvastatin effects on brain atrophy and …

Background: Progressive forms of multiple sclerosis (MS) affect more than 1 million
individuals globally. Recent approvals of ocrelizumab for primary progressive MS and …

Background: Definitions for reliable identification of transition from relapsing-remitting
multiple sclerosis (MS) to secondary progressive (SP) MS in clinical cohorts are not …

There is evidence that multiple sclerosis (MS) pathology leads to distinct patterns of volume
loss over time (VLOT) in different central nervous system (CNS) structures. We aimed to use …

Background There are 4 courses of multiple sclerosis (MS): clinically-isolated syndrome
(CIS), relapsing-remitting MS (RRMS), primary-progressive MS (PPMS) and secondary …

The activity of kallikrein-related peptidase 6 (KLK6) is deregulated in various diseases such
as cancer and neurodegenerative diseases. KLK6 is thus considered as an attractive …